Navigation Links
Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C

on PROVE 2 data, regimens that may exclude RBV. Vertex expects to focus on treatment durations of no more than 24 weeks. Vertex and Tibotec are planning to meet with regulatory authorities to discuss the Phase 3 design in mid-2007 and are planning to initiate Phase 3 clinical development in the fourth quarter of 2007. The registration strategy and timing of an NDA filing will be dependent on discussions with regulatory authorities.

PROVE 1 Results at EASL

Interim 12-week antiviral analysis of PROVE 1

A total of 250 patients were enrolled in PROVE 1 and received at least one dose of telaprevir or placebo in addition to Peg-interferon alfa-2a (peg-IFN) + ribavirin (RBV) in the study. A total of 175 patients received at least one dose of telaprevir in 1 of 3 arms (treatment arms B, C and D) and 75 patients received at least one dose of placebo (arm A). Treatment with telaprevir resulted in a high proportion of patients achieving a rapid viral response at 4 weeks. At the time of the interim analysis, all patients had either completed 12 weeks or discontinued from the study prior to week 12. Available 4-week and 12-week results are detailed in the following table: -0-

 Interim HCV RNA results for Patients Enrolled in the PROVE 1 Trial

---------------------------------------------------------------------

Treatment Assignment            Patients Patients Patients Patients

                                 with     with     with     with HCV

                                 HCV RNA  HCV RNA  HCV RNA  RNA (less

                                 (less    (less    (less    than)10

                                 than)30  than)10  than)10  IU/mL at

                                 IU/mL    IU/mL    IU/mL    end of 12

                                 at end   at end   at end   weeks of

                                 of 4     of 4     of 12    dosing

                                 weeks    weeks    weeks    (last on-

                 
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
(Date:8/28/2015)... 2015 Research and ... of the "Investigation Report on China,s Quetiapine ... Developed by AstraZeneca plc, quetiapine (under the ... for the treatment of schizophrenia. Approved by CFDA ... in the Catalogue of Drugs for the Basic ...
(Date:8/28/2015)... August 28, 2015 The scientific team ... with one of the leading academics in the field of ... record holder in life extension for model animals - 10 ... of aging and age-related diseases, primarily, around the stability and ... just been published as "Stability analysis of a model gene ...
(Date:8/28/2015)... Denmark and ATLANTA ... 31, 2015 the US Food and Drug Administration (FDA) cleared ... Depressive Disorder in adult patients who have failed to receive ... TMS is a non-invasive technique for stimulating neural tissue in ... Major Depressive Disorder. The procedure has been proven safe and ...
Breaking Medicine Technology:China Quetiapine Market Investigation Report 2010-2019 2Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3
... enrollment is complete in,the first randomized, prospective, ... and cost-effectiveness of a physiologic-guided,percutaneous coronary intervention ... with multivessel coronary artery disease (CAD). Bernard ... today at the Transcatheter,Cardiovascular Therapeutics symposium (TCT ...
... Phase III - - Conference Call Scheduled ... LA JOLLA, Calif., Oct. 22 TorreyPines,Therapeutics, Inc. (Nasdaq: ... endpoint in a 306-patient, Phase IIb clinical trial for ... study, which evaluated,tezampanel administered subcutaneously, the 40 mg dose ...
Cached Medicine Technology:Patient Enrollment Complete in First Trial to Compare Physiologic Guidance vs. Angiographic Guidance of Stent Deployment in Patients with Multivessel Disease 2Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache 2Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache 3Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache 4Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache 5Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache 6Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache 7Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache 8
(Date:8/29/2015)... NY (PRWEB) , ... August 29, 2015 , ... Next ... end of summer (which astronomically, officially ends on September 22nd this year). For IT ... cyber security hangovers linger on which could prove far more costly than a simple ...
(Date:8/29/2015)... Calgary, AB (PRWEB) , ... August 29, 2015 ... ... congestive heart failure, angina, chronic obstructive pulmonary disease (including emphysema), or asthma, are ... conditions such as angina, previous heart attack, heart failure or heart-rhythm problems (arrhythmia ...
(Date:8/29/2015)... ... , ... The popular television program VOICES IN AMERICA, hosted by legendary star ... devoting an entire short segment to the subject of diabetes. Diabetes is a debilitating ... daily basis, but recent advancements in medical science may prove to be a significant ...
(Date:8/28/2015)... (PRWEB) , ... August 29, 2015 , ... Rio ... higher learning and the student experience as part of the EDUCAUSE - Next Generation ... Foundation . , This is the third Breakthrough Models Incubator hosted by ...
(Date:8/28/2015)... ... August 28, 2015 , ... An online provider of CPAP machines, ... purchase of CPAP equipment more affordable by offering shipping at no cost to you, ... products and orders of any size. My Cpap Store is located in Las Vegas, ...
Breaking Medicine News(10 mins):Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2
... , SAN DIEGO, Nov. 24 US ... Nursery and Wellness products is pleased to announce it has ... for its Aloe365(TM) Juice product. , Yan ... pleased to announce that we have completed the certification process ...
... , 2009 Q3 Financials, S-1 Registration Statement being Prepared ... WESTON, Fla., Nov. 24 American Scientific Resources Inc. (Pink Sheets: ... update. , Since filing 2007 and 2008 audited financials on Pinksheets ... all part of a long term business plan for the Company. ...
... BATTLE CREEK, Mich., Nov. 24 The following should be ... W.K. Kellogg Foundation: , The W.K. Kellogg Foundation commends Congress ... substantially strengthen oral health care for our most vulnerable children. ... a high water mark for oral health legislation, with more ...
... reasoning that testing less is OK , TUESDAY, Nov. 24 ... upended in the past two weeks. , Not only did ... age at which it recommends women get their first mammogram ... and Gynecologists (ACOG) decided that adolescents should be spared the ...
... Health ... suggests the need to re-examine reimbursement. , ... Alpharetta, GA (Vocus) November 24, 2009 -- The proposed legislation ... insurers, legislators and policy makers all weighing in with their views on what will ...
... ... advice on the topic of most concern to MyShrink readers. a - ban,- don: ... ... 2009 -- Dr. Suzanne LaCombe and Dr. Carole Gaato today announced the second webinar ...
Cached Medicine News:Health News:US Farms, Inc. Receives American Vegetarian Association Certification Approval for Aloe365(TM) Juice Product 2Health News:American Scientific Resources Inc. Issues Corporate Update 2Health News:American Scientific Resources Inc. Issues Corporate Update 3Health News:Statement of Support: Strengthening Oral Health Care is Key Part of Health Reform 2Health News:Recent Cancer Screening Changes Leave Many Confused 2Health News:Recent Cancer Screening Changes Leave Many Confused 3Health News:Recent Cancer Screening Changes Leave Many Confused 4Health News:Jackson & Coker Industry Report Addresses Health Care Reform 2Health News:Jackson & Coker Industry Report Addresses Health Care Reform 3Health News:Home For the Holidays: MyShrink.com Announces the Second in its Successful Six-Part Webinar Series: "Abandonment: The Hidden Fear" 2
... Rim Implants provide the surgeon ... augmentation of the inferior and ... or secondary rim repair. The ... projection and extends around the ...
Flattened points in vertical plane, straight shafts, cross action, round handle....
Phaco chopper delicate rounded tip....
Nucleus chopper....
Medicine Products: